Navigation Links
Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
Date:10/6/2008

dverse event (13.8% versus 16.0%).

-- Across the Contrave Phase 3 trial experience to date, only 7.6% of all reported adverse events led to an early discontinuation from the trials.

In summary, naltrexone SR met its primary objectives by providing a lower peak plasma concentration (Cmax) than the legacy IR formulation while retaining a similar total plasma exposure (AUC). This held true both for the parent molecule (naltrexone) and its principal active metabolite (6-beta-naltrexol). In a Phase I pilot study, improved tolerability was suggested amongst those who received naltrexone SR / bupropion SR than those receiving the prior Phase 2 formulation containing naltrexone IR. Finally, in a blinded, pooled analysis of preliminary Phase 3 data, results suggest that naltrexone SR / bupropion SR may be associated with decreased rates of treatment-emergent nausea, headache, dizziness, or discontinuation due to an adverse event.

About Orexigen(R) Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing drug combinations for use in schizophrenia and obsessive-compulsive disorder. Further information about the company can be found at http://www.Orexigen.com.

About Contrave(R)

Contrave is an investigational weight loss medication with a mechanism of action that works at two sites within the central nervous system. The first is a hypothalamic site that controls the balanc
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)...  Vivex Biomedical, Inc., a leading processor of human ... today that it hired Lou Barnes as ... Vivex Biomedical formed UMTB Biomedical as a wholly-owned subsidiary ... in November 2014. UMTB is the oldest tissue bank ... twenty-five year veteran of the tissue banking industry, having ...
(Date:3/2/2015)... -- Akron Children,s Hospital has been designated a Diagnostic Imaging ... Radiology (ACR), making it the first hospital in ... in the United States to ... the ACR as a DICOE provides validation that our ... national benchmarks," says Dr. Michael Rubin , chairman, ...
(Date:3/2/2015)... 2, 2015  Kush Bottles, North ... solutions for the marijuana industry, announced today that ... been nominated for a 2015 Excellence in Entrepreneurship ... Award is designed to recognize individuals who exemplify ... their creativity and determination, have established and nurtured ...
Breaking Medicine Technology:Vivex Biomedical, Inc. Announces New Chief Operating Officer of Tissue Bank 2Vivex Biomedical, Inc. Announces New Chief Operating Officer of Tissue Bank 3Akron Children's designated ACR Diagnostic Imaging Center of Excellence 2Kush Bottles CEO, Nicholas Kovacevich, Nominated for 2015 "Excellence in Entrepreneurship Award" 2
(Date:3/2/2015)... Today the Brain Injury Association of America (BIAA) officially kicked ... support the more than 5.3 million Americans who are living ... nation in observing Brain Injury Awareness Month by conducting an ... the 2015 to 2017 campaign is: Not Alone. , ... general public about the incidence of brain injury and the ...
(Date:3/2/2015)... Market Publishers Ltd is extremely happy ... Global Industry Analysts Inc and recently added to its ... . Through 2018, the global radiation therapy equipment market ... research report suggests a holistic analysis of the situation ... well as covers the top market trends. The publication ...
(Date:3/2/2015)... 02, 2015 Tyrone Christopher, Co-founder of ... medium for the model agency industry, have launched Softcandy.sexy, ... Mango, Passion Fruit, Pink Grapefruit, Pomegranate, and or Vanilla ... 1pm. , At a cost of alienating a few ... fire by announcing the brands commitment and support of ...
(Date:3/2/2015)... 02, 2015 After a rigorous evaluation ... service, pricing and long-term strategy, Blood Centers of America ... choice for member centers’ testing needs. , BCA, which ... more than 30 percent of the U.S. blood supply, ... “BCA is committed to drive cost savings to members,” ...
(Date:3/2/2015)... View, CA (PRWEB) March 02, 2015 ... today that it has officially launched a multivitamin ... Gustafsson, head of product development for BNatrl, said ... through feedback from Olympic and other world-class athletes. ... excited to use this pure whole food multivitamin ...
Breaking Medicine News(10 mins):Health News:Brain Injury Association of America Launches “Not Alone” Campaign for Brain Injury Awareness Month 2Health News:New Topical Research Reports Prepared by GIA Now Available at MarketPublishers.com 2Health News:New Topical Research Reports Prepared by GIA Now Available at MarketPublishers.com 3Health News:Sex Sells! A Newly Minted Organic Bodycare Brand Courts Controversy at a Cost 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 3Health News:Bnatrl Launches Multivitamin Supplement for Runners 2
... ... a permanent solution to the Medicare physician payment system this year, says MedicareSupplementPlans.com ... Los ... year designed to improve the way Medicare pays physicians while still keeping Medicare costs ...
... , Senate Finance Committee Urged Not to Include ... WASHINGTON, Aug. 7 America,s local and regional independent ... provision imposing a 20% co-pay on laboratory services under Medicare. ... this provision would shift billions of dollars in costs to senior ...
... Duane Reade Holdings, Inc. announced today that its wholly-owned ... had closed their offering of $300.0 million aggregate principal amount ... The Notes bear interest at an annual rate of ... yield to maturity of 12.375%. The Notes were issued ...
... serious cardiovascular issues: study , FRIDAY, Aug. 7 (HealthDay ... is a reliable predictor of cardiovascular complications in people ... -- kidney damage caused by diabetes. , The study ... 2007. Those with increased levels of IgM in their ...
... , , , ... will learn how to use the latest technology to help keep ... California Partnership to End Domestic Violence (CPEDV) and Verizon. , ... the Verizon Foundation, the philanthropic arm of Verizon, is designed to ...
... the Yerkes National Primate Research Center, Emory University, believe ... explored in the development of an effective AIDS vaccine. ... nonhuman primates, they propose an additional new approach to ... in the August issue of Nature Medicine . ...
Cached Medicine News:Health News:Congress Unlikely to Pass Permanent Medicare Physician Payment Fix in 2009, says MedicareSupplementPlans.com 2Health News:Seniors: Get Your Checkbooks Ready 2Health News:Duane Reade Holdings, Inc. Announces Closing of Offering of $300 Million of 11.75% Senior Secured Notes Due 2015 2Health News:Duane Reade Holdings, Inc. Announces Closing of Offering of $300 Million of 11.75% Senior Secured Notes Due 2015 3Health News:Immunoglobulin Can Predict Some Diabetic Complications 2Health News:Verizon and California Partnership to End Domestic Violence Launch Program to Help Victims Protect Themselves by Using Technology 2Health News:Verizon and California Partnership to End Domestic Violence Launch Program to Help Victims Protect Themselves by Using Technology 3Health News:Verizon and California Partnership to End Domestic Violence Launch Program to Help Victims Protect Themselves by Using Technology 4Health News:Yerkes researchers propose ambitious new strategies for AIDS vaccine research 2Health News:Yerkes researchers propose ambitious new strategies for AIDS vaccine research 3
Excellent during IOL insertion while pushing the trailing haptic into position. Gently curved shaft and round handle....
Ideal for nucleus manipulation during phacoemulsification. Also used for manipulating and rotating IOLs within the anterior chamber. Round knurled handle...
Short, narrow paddle angled 45 degree inserts through the side port stab incision and is ideal for effective manipulation of the lens during anterior chamber phacoemulsification....
Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique. Round knurled handle. Manufactured in titanium....
Medicine Products: